CRO concept stocks experienced a rapid surge in the afternoon session. As of press time, WUXI BIO (02269) rose 4.94% to HK$32.28, GENSCRIPT BIO (01548) gained 3.8% to HK$15.01, WUXI APPTEC (02359) climbed 2.62% to HK$99.95, and TIGERMED (03347) increased 1.22% to HK$38.04.

The rally followed WUXI BIO's announcement on December 2 of a strategic cooperation memorandum with the Qatar Free Zones Authority (QFZ), expanding its global service network and professional capabilities to the Middle East. This partnership lays the foundation for WUXI BIO to establish its first integrated CRDMO center in the region.

Bank of Communications International released a research report stating that CXO sector orders and performance are showing clear signs of recovery by 2025. The report projects that with improving downstream financing and growing overseas expansion trends, the sector could maintain strong earnings growth in 2026. However, amid tightening U.S. pharmaceutical regulations and increasing drug development complexities, industry consolidation is just beginning, likely leading to the elimination of outdated capacities and weaker players. Consequently, leading companies in high-growth segments are expected to demonstrate stronger long-term stability.